Volume Alert: Gilead Sciences, Inc. (NASDAQ:GILD), NPS Pharmaceuticals, Inc ... Market News Call It demonstrated “highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. Is GILD A Strong At The GALE? Get Advantage Of Our Free ... |
